Jounce Therapeutics, Inc. (JNCE) Social Stream



Jounce Therapeutics, Inc. (JNCE): $6.17

0.16 (+2.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JNCE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

Jounce Therapeutics Inc (JNCE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Jounce Therapeutics Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
6 $17 $15 $15.5 $8.31 86.52%

Over the past 18 months, JNCE's average upside potential has been 68.66%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-05 6 17 15.0 15.50 9.19 68.66%
2020-11-06 7 15 5.5 9.38 NA NA%
2020-09-17 6 28 5.5 14.30 NA NA%
2020-08-07 6 15 5.5 10.62 NA NA%
2020-05-12 6 15 5.5 9.88 NA NA%

JNCE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.17 3 1 1 1 1 6

The Trend in the Broker Recommendations


JNCE's average broker recommendation rating improved by 0.5 over the prior 20 months.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • Jounce Therapeutics Inc's variance in analysts' estimates is lower than 87.82% of Pharmaceutical Products stocks.
  • The average analyst price target of JNCE is greater than 18.4% of all US stocks.
  • The number of analysts covering the stock of JNCE is greater than 79.6% of stocks in the small market cap category.
  • Jounce Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 78.38% of all US stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Jounce Therapeutics Inc are GRFS, AMRX and ABCM.

Is JNCE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.2613 seconds.